Fugenbio announced that the research result of ‘Serliporia lock Serrata’ mycelium not only improves diabetes but also suppresses the pathology related to symptoms in animals that cause cognitive impairment was published in the SCI-level international academic journal ‘Food science & biotechnology’ 8 work said
In a paper titled ‘Effect of Scopolamine-Induced Memory Impairment in Mice with Memory Impairment’, a joint study with Professor Kim Sang-sang’s research team at Kyungpook National University, the research team found that Seriporia rock Serrata was able to improve memory and cognitive abilities. It was confirmed that it showed effects such as improvement and alleviation of hippocampal tissue damage.
In addition, as pharmacological mechanisms of action, free radical scavenging activity, oxidative stress suppression, and antioxidant enzyme-inducing activity were investigated. This suggests that the brain nerve cell protective effect of S. Lipo Ria lock Serrata, which is differentiated from existing substances, can be linked to the effect of improving the cognitive function of the human body.
Kim Jung-hwan, head of Fugenbio’s research division, said, “This study confirmed the potential inhibitory effect of C. lock serrata from Alzheimer’s disease, which occurs when insulin resistance induces amyloid beta plaque, inflammation and oxidative stress in the brain, and is an unprecedented intractable disease. It presents new possibilities as a therapeutic substance for
According to ‘JAMA Neurology 2016’, a study conducted by Dr. Sanjay Asthana at the University of Wisconsin, USA, insulin resistance causes cognitive decline. increased. In other words, if the brain does not use enough fuel due to insulin resistance, the memory deteriorates and interferes with daily life, which in turn can lead to Alzheimer’s disease.
According to the International Association for Alzheimer’s Disease (ADI), the number of dementia patients worldwide increased from 46.78 million in 2015 to 50 million in 2018, an increase of 3 million in three years. ADI predicts that the number of dementia patients will continue to increase from 75 million in 2030 to 131.5 million in 2050.
The same is true of the domestic situation. According to the statistics of the Central Dementia Center, as of February 2021, it is estimated that there are 863,542 people with dementia among over 60% of the elderly in Korea. The prevalence of dementia in the population over 65 years old is 10.33%. This number is expected to exceed 1 million in 2024, which is rapidly increasing every year.
As the proportion of dementia patients is increasing due to the aging of the global population, countries are investing astronomical costs and efforts to develop dementia treatments, but no treatments have been developed yet. Dementia drugs on the market are largely divided into acetylcholinesterase inhibitors and NMDA receptor antagonists depending on the mechanism of development. There are three types of acetylcholinesterase inhibitors: donepezil, rivastigmine, and galantamine, and memantine is an NMDA receptor antagonist. These four drugs do not restore damaged nerve cells, but are known to help maintain cognitive function and delay disease progression.
Since brain cells, once damaged, cannot be regenerated, protection of brain cells from damage is the only solution at present, for which no special treatment has been developed. Therefore, the company’s explanation is that the protective effect on the brain nerve cells of C. locksera ta revealed through this study is very significant.
Meanwhile, in 2020, Fugenbio launched ‘Sephona’, which is the world’s first in the world to improve the insulin resistance index (HOMA-IR), which has been proven through a human test, and has been developed in the United States, Japan, Germany, China, and China. It holds about 30 original patents related to Serliporia Lock Serrata in major countries such as Canada.
